Mix-and-match vaccines highly effective against COVID-19: Lancet study
3 years, 2 months ago

Mix-and-match vaccines highly effective against COVID-19: Lancet study

Deccan Chronicle  

London: People who received a first dose of the Oxford-AstraZeneca COVID-19 vaccine followed by an mRNA vaccine shot had a lower risk of infection compared to those immunised with both doses of the AstraZeneca preventive, according to a nationwide study in Sweden. "However, our study shows a greater risk reduction for people who received an mRNA vaccine after having received a first dose of a vector-based, as compared to people having received the vector-based vaccine for both doses," Nordstrom said. During a 2.5-month average follow-up period after the second dose, the study showed a 67 per cent lower risk of infection for the combination of AstraZeneca and Pfizer vaccine shots. There was a 79 per cent lower risk of infection for AstraZeneca and Moderna vaccine shots, compared to unvaccinated individuals, the researchers said.

Risk Sweden Received Study Vaccine Mrna Dose  effective  covid19  lancet  received  highly  mixandmatch  vaccines  study  infection  vaccine  researchers  health  dose  risk  compared  doses

History of this topic

Covishield Side Effects: Doctors' Group Urges Govt to Review All Covid Vaccines
7 months, 1 week ago

Covishield Side Effects: Doctors' Group Urges Govt to Review All Covid Vaccines

News 18  

In the wake of pharmaceutical giant AstraZeneca admitting in a UK court that its Covid vaccine can cause blood clots in rare cases, a group of doctors on Thursday expressed deep concern over the safety of the Covishield vaccine manufactured by the Serum Institute of India. At a press conference, the doctors, under the banner of the Awaken India Movement, …

AstraZeneca withdraws Covishield pointing to low demand, but did rare side effects also play a role?
7 months, 2 weeks ago

AstraZeneca withdraws Covishield pointing to low demand, but did rare side effects also play a role?

The Hindu  

Published : May 09, 2024 13:21 IST - 3 MINS READ The pharmaceutical giant AstraZeneca has reportedly withdrawn its COVID-19 vaccine Vaxzevria, also known as Covishield, worldwide, citing commercial reasons for the decision. Vaxzevria saved millions of lives AstraZeneca, who developed the vaccine with Oxford University, said it was “incredibly proud of the role Vaxzevria played in ending the global …

AstraZeneca's Covishield Showed Lowest Incidence of Side Effects in India Versus Globally, Says Top Govt Official
7 months, 2 weeks ago

AstraZeneca's Covishield Showed Lowest Incidence of Side Effects in India Versus Globally, Says Top Govt Official

News 18  

AstraZeneca’s vaccine has demonstrated the lowest incidence of side effects in India compared to the global average, a top government official involved in the national roll-out of Covid-19 vaccination told News18. “But only around 50 cases witnessed Thrombosis with Thrombocytopenia Syndrome — a rare side effect caused by the jab — of the 180 crore doses administered against 4 to …

After AstraZeneca covid-19 vax recall worldwide, Serum says it stopped manufacturing jabs in Dec 2021
7 months, 2 weeks ago

After AstraZeneca covid-19 vax recall worldwide, Serum says it stopped manufacturing jabs in Dec 2021

Live Mint  

New Delhi: The Serum Institute of India on Wednesday said it has stopped making and supplying covid-19 vaccine Covishield after AstraZeneca, the British drugmaker that helped develop the vaccine, announced it too was withdrawing its version of the jab worldwide. The development follows the launch of a class action suit in the UK over allegations that the UK vaccine caused …

Covishield vaccine has had more benefits than risks, says study by Kozhikode doctors
7 months, 2 weeks ago

Covishield vaccine has had more benefits than risks, says study by Kozhikode doctors

The Hindu  

At a time when the safety aspects of the Covishield vaccine have kicked up a row, a retrospective study by two doctors from Kozhikode has claimed that its risks are minimal in view of the benefits. The controversy arose after pharmaceutical company AstraZeneca admitted in the High Court of London, United Kingdom, that its vaccine against COVID-19 had the potential …

Only 7 Out 10 Lakh May Face Clotting Risk Due to Covishield: Former ICMR Scientist
7 months, 3 weeks ago

Only 7 Out 10 Lakh May Face Clotting Risk Due to Covishield: Former ICMR Scientist

News 18  

Only seven to eight individuals out of 10 lakh, who receive the coronavirus vaccine Covishield, face the risk of experiencing a rare side effect known as thrombosis thrombocytopenia syndrome. India’s top epidemiologist, former ICMR scientist Dr Raman Gangakhedkar, said those who got this vaccine have “no risk at all”. Gangakhedkar, who is known for his simplistic approach to clearing complicated …

AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns
7 months, 3 weeks ago

AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns

India TV News  

In response to recent concerns regarding potential rare side effects associated with the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical company has underscored its unwavering commitment to patient safety while affirming the vaccine's overall safety profile. This comes in the wake of a recent admission by AstraZeneca, the pharmaceutical company, that its Covid vaccine Covishield and Vaxzevria "can, in very rare cases, …

Covishield more effective than Covaxin: Study
9 months, 2 weeks ago

Covishield more effective than Covaxin: Study

New Indian Express  

BENGALURU: Covishield vaccine had higher antibody response compared to Covaxin during the pandemic, according to a study by a consortium of 11 institutions led by scientists from the National Centre for Biological Sciences, Bengaluru. In all, 691 people aged between 18 and 45, mostly from Bengaluru and Pune, were part of the study.’Immunogenicity of SARS - CoV-2 vaccines Covaxin and …

What study on Covishield versus Covaxin vaccine reveals
9 months, 2 weeks ago

What study on Covishield versus Covaxin vaccine reveals

The Hindu  

March 07, 2024 10:59 am | Updated March 09, 2024 10:53 am IST - Bengaluru A new study by a consortium of 11 institutes, led by scientists from the National Centre for Biological Sciences, has found that the Covishield vaccine demonstrated more robust immune responses compared to Covaxin. The key findings state that Covishield, leveraging a virus vector to deliver …

New COVID variant JN.1: Health Ministry says no need for booster dose
11 months, 4 weeks ago

New COVID variant JN.1: Health Ministry says no need for booster dose

The Hindu  

Following the Union Health Ministry direction that States be alert and prepared for any possible surge in COVID-19 cases following the emergence of the new variant JN.1, senior health officials said that there is no move to recommend administration of vaccine booster dose for India. India saw a single-day rise of 656 COVID-1 infections while the active cases have increased …

Oxford AstraZeneca Covid jab was ‘defective’, claims landmark legal case
1 year, 1 month ago

Oxford AstraZeneca Covid jab was ‘defective’, claims landmark legal case

The Telegraph  

As many as 80 claimants could lodge legal cases with the High Court by the end of the year in a class action that threatens to undermine faith in the rollout of the AstraZeneca vaccine that was developed jointly with Oxford University. In Mr Scott’s claim, his lawyers argue that he suffered “personal injuries and consequential losses arising out of …

At 14,493, India records sharp dip in daily Covid tally, logs 801 new cases
1 year, 7 months ago

At 14,493, India records sharp dip in daily Covid tally, logs 801 new cases

Hindustan Times  

India has logged 801 new coronavirus infections, while the active cases have dipped to 14,493 from 15,515, according to the Union Health Ministry data updated on Monday. According to the ministry's website, 220.66 crore doses of Covid vaccine have been administered in the country so far under the nationwide vaccination drive. The active cases now comprise 0.03 per cent of …

India restarts Covid vaccine production as new infections soar 30% in one day
1 year, 8 months ago

India restarts Covid vaccine production as new infections soar 30% in one day

The Independent  

India is ramping up its vaccine production following a rapid surge in Covid-19 cases driven by a new subvariant dubbed Arcturus. The country recorded 10,158 news Covid cases on Thursday, a 30 per cent surge in one day, according to the federal health ministry data. The company stopped manufacturing Covishield in December 2021 due to dwindling demand and a low …

Serum Institute could resume Covishield production as Covid cases rise
1 year, 8 months ago

Serum Institute could resume Covishield production as Covid cases rise

Live Mint  

The Serum Institute of India could resume production of the Covishield Covid-19 vaccine as infections rise in the country, a company spokesperson said on Wednesday. Dr Amitav Banerjee - an epidemiologist who leads DY Patil Medical College in Pune has earlier said that Covishield carried a ‘double whammy of risk’. Many would perhaps not know that Covishield carries a DNA …

Studies show XBB.1.16 is not clinically more severe
1 year, 8 months ago

Studies show XBB.1.16 is not clinically more severe

Hindustan Times  

The XBB.1.16 sub-variant of the Omicron strain of the SARS-CoV-2 virus that causes Covid does not exhibit higher clinical severity according to preliminary results from laboratory studies being conducted in the country to know disease characteristics, according to people familiar with the matter. According to the World Health Organisation, mutations at position 478 of the SARS-CoV-2 spike protein have been …

’Covishield shouldn’t have been rolled out’: Doctor flags ’severe’ side-effects
1 year, 10 months ago

’Covishield shouldn’t have been rolled out’: Doctor flags ’severe’ side-effects

Live Mint  

A well known British-Indian cardiologist has flagged the cardiovascular side effects of the Covishield vaccine. According to Dr Aseem Malhotra, the vaccine manufactured in India by the Serum Institute is ‘even worse’ than mRNA COVID-19 vaccines when it came to concerns such as heart attacks and strokes. Citing a comparison published in a peer-reviewed journal, he said that the Oxford-AstraZeneca …

Time to Join this ‘Herd’: 39% Have Boosted Their Protection against Covid Virus, Finds Survey
1 year, 11 months ago

Time to Join this ‘Herd’: 39% Have Boosted Their Protection against Covid Virus, Finds Survey

News 18  

At least 39% of respondents have already taken the Covid vaccine booster dose, while 6% plan to take the injectable booster and 4% the nasal one, a LocalCircles survey has found. Amid the uptick in Covid in cases in China and other countries, the Centre gave nod for Bharat Biotech’s intranasal COVID vaccine iNCOVAAC as a booster dose. Director General …

Covishield Immune Responses Against Covid Variants Higher Than Covaxin: Study
1 year, 11 months ago

Covishield Immune Responses Against Covid Variants Higher Than Covaxin: Study

News 18  

Neutralising antibody responses against the SARS-COV-2 virus and its variants of concern are higher among Covishield recipients than those who took the indigenously made Covaxin, according to a multi-centre study. Covishield elicited immune responses of higher magnitude and breadth than Covaxin in both seronegative individuals and seropositive individuals, across cohorts representing the pre-vaccination immune history of the majority of the …

No second Covid-19 booster dose required: Report
1 year, 11 months ago

No second Covid-19 booster dose required: Report

Live Mint  

There is no need to take a second booster dose against Covid-19 infection, news agency ANI reported on Tuesday citing government sources. According to the data by the Union Health Ministry, a total of 220.11 crore vaccine doses have been administered in the country, of which 95.13 crore have taken the second dose while only 22.41 crore of the population …

Omicron BF.7: Is mixing Covid vaccines more effective against the new subvariant? What experts say
1 year, 11 months ago

Omicron BF.7: Is mixing Covid vaccines more effective against the new subvariant? What experts say

Hindustan Times  

Amid rising cases of Omicron BF.7 in China and other parts of the world, there has been concerns of a fresh wave triggered by the subvariant in India in the coming months. However, mixing the vaccines has no side effects rather it can boost the immunity and give multiple ways to our immune system to identify the offending virus and …

COVID-19 vaccines offer significant protection against reinfection: Study
2 years, 1 month ago

COVID-19 vaccines offer significant protection against reinfection: Study

India TV News  

COVID-19 vaccine: A recent study revealed that people earlier infected with the SARS-CoV-2 virus still benefit from vaccination against COVID-19, gaining 60% to 94% protection against reinfection. “In our study, we find a significant vaccine effectiveness against SARS-CoV-2 reinfection, and this shows the importance of vaccination also for those who might be protected by natural immunity," said Katrine Finderup Nielsen …

Explained | Can vaccine distribution be made fairer?
2 years, 1 month ago

Explained | Can vaccine distribution be made fairer?

The Hindu  

The story so far: The Global Dashboard for Vaccine Equity, a joint effort by the United Nations Development Programme, the World Health Organization and the University of Oxford with cooperation across the UN system, has put out recent data that justifies the vexatious core of the vaccine distribution programme: Only one in four people has been vaccinated with at least …

Study confirms AstraZeneca jab’s higher risk of very rare clot
2 years, 1 month ago

Study confirms AstraZeneca jab’s higher risk of very rare clot

The Hindu  

AstraZeneca's Covid vaccine has been linked to a 30% higher risk of getting a very rare blood clotting condition compared to the Pfizer jab, a large international study said Thursday. Several countries have already altered their advice after previous research indicated that -- in a tiny number of cases -- thrombosis with thrombocytopenia syndrome can be a possible side effect …

AstraZeneca Covid Jab Linked to 30% Higher Risk of Very Rare Blood Clot: Study
2 years, 1 month ago

AstraZeneca Covid Jab Linked to 30% Higher Risk of Very Rare Blood Clot: Study

News 18  

AstraZeneca’s Covid vaccine has been linked to a 30-percent higher risk of getting a very rare blood clotting condition compared to the Pfizer jab, a large international study said Thursday. Several countries have already altered their advice after previous research indicated that — in a tiny number of cases — thrombosis with thrombocytopenia syndrome can be a possible side effect …

CORBEVAX offers better immunity as a heterologous booster shot
2 years, 2 months ago

CORBEVAX offers better immunity as a heterologous booster shot

Deccan Chronicle  

HYDERABAD: Heterologous booster shots have gained significance in light of the waning effect of vaccine doses, especially against different variants of the Covid-19 virus. There is an increase in the immune response to the administration of heterologous booster shots on two counts – first cellular immunity and second, neutralizing antibodies. Administering the CORBEVAX vaccine as a heterologous booster dose provides …

AstraZeneca Nasal Spray Vaccine for Covid-19 Suffers Setback in Early Trial
2 years, 2 months ago

AstraZeneca Nasal Spray Vaccine for Covid-19 Suffers Setback in Early Trial

News 18  

In a major setback, AstraZeneca and the University of Oxford’s joint trial for the nasal-spray version of the Nonreplicating viral vector vaccine against Covid-19 did not yield desired protection, reported Reuters on Tuesday. The University of Oxford said, “An antibody response in the respiratory mucous membranes was seen in only a minority of participants in the trial, which was in …

Will Two ‘Made-in-India’ Vaccines Be the New Covid Boosters? News18 Decodes Differences
2 years, 3 months ago

Will Two ‘Made-in-India’ Vaccines Be the New Covid Boosters? News18 Decodes Differences

News 18  

India will soon roll out mRNA shots and intranasal vaccines, which will be available on CoWIN, and can be used as boosters against Covid-19. India’s first mRNA shot is only the third mRNA vaccine to be approved for Covid-19 in the world after Pfizer and Moderna. But mortality will be reduced.” Sharing a study of the intranasal vaccines under clinical …

An End to Foreign-return Vaccine Woes: India to Offer Remaining Covid-19 Shots Domestically
2 years, 3 months ago

An End to Foreign-return Vaccine Woes: India to Offer Remaining Covid-19 Shots Domestically

News 18  

Individuals who have received Covid-19 vaccines abroad and wish to get their second dose or booster shot in India can now do so. The development comes following an August 18 report by the Times of India which highlighted the issues people who had been jabbed abroad faced when they tried to receive a second or third shot here because the …

How India Pursued Covid-19 Vaccine Diplomacy Amid Vaccine Nationalism By Rich Nations
2 years, 4 months ago

How India Pursued Covid-19 Vaccine Diplomacy Amid Vaccine Nationalism By Rich Nations

ABP News  

The last 30 months have seen the world getting ravaged by Covid-19. When rich nations of the Global North were stockpiling and hoarding Covid-19 vaccines, many times more than their population, India not only spearheaded one of the largest vaccine drives within the country but also shared the vaccine doses with low- and middle-income countries worldwide. India supplied 23.9 crore …

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report
2 years, 4 months ago

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report

Live Mint  

The government has approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin, news agency PTI has reported on 10 August citing official sources. "Corbevax will be considered as a precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of …

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients
2 years, 4 months ago

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients

News 18  

The Centre has approved Biological E’s Corbevax as a Covid-19 precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. Union Health Secretary Rajesh Bhushan said, “Corbevax will be available as precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield vaccines …

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon
2 years, 4 months ago

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon

News 18  

The Union health ministry is expected to soon approve Biological E’s Corbevax as a precaution dose for people above 18 years who are double vaccinated with either Covishield or Covaxin, official sources said on Tuesday. “Corbevax will be considered as a precaution dose after completion of 6 months or 26 weeks from the date of administration of the second dose …

Go For More Tests, Faster Vaccination: Worried by Uptick in Covid Graph, Centre's Advisory to 7 States
2 years, 4 months ago

Go For More Tests, Faster Vaccination: Worried by Uptick in Covid Graph, Centre's Advisory to 7 States

News 18  

Ramp up testing, promote Covid-appropriate behaviour and increase the pace of vaccination, the Centre has told Delhi and six states amid a spike in coronavirus cases, especially ahead of the festive season. The state must also closely monitor districts reporting higher cases, positivity rates and clusters to prevent further spread of infection and effective case management,” he stressed in the …

Adults may get different vaccine as booster shot instead of Covishield, Covaxin
2 years, 4 months ago

Adults may get different vaccine as booster shot instead of Covishield, Covaxin

Live Mint  

As the government has continued to emphasize Covid booster doses due to the rising number of cases, a panel has recommended a different vaccine for Indian adults. Government panel National Technical Advisory Group on Immunisation has recommended Biological E's Corbevax as a precaution dose for adults fully vaccinated with either Covishield or Covaxin. "Corbevax may be considered for a third/precaution …

Data | Less than 4% Indians got COVID-19 booster dose, among lowest in the world
2 years, 5 months ago

Data | Less than 4% Indians got COVID-19 booster dose, among lowest in the world

The Hindu  

After reducing the gap between the second dose and the precautionary dose of the COVID-19 vaccine from nine to six months for adults, the government on Wednesday announced free booster shots for adults for the next 75 days. Strikingly, India’s progress in the administration of the first two doses was relatively better, with 65.5% of the population getting both shots, …

India reports over 20,000 new COVID-19 cases after 145 days
2 years, 5 months ago

India reports over 20,000 new COVID-19 cases after 145 days

The Hindu  

Daily COVID-19 cases in India were recorded over 20,000 after a gap of 145 days while the active cases increased to 1,36,076, according to the Union Health Ministry data updated on Thursday, July 14, 2022. A total of 20,139 new COVID-19 cases were reported in a span of 24 hours, pushing the total tally of cases to 4,36,89,989. The active …

Over 42 lakh deaths in India prevented by COVID-19 vaccines in 2021: Lancet study
2 years, 6 months ago

Over 42 lakh deaths in India prevented by COVID-19 vaccines in 2021: Lancet study

The Hindu  

COVID-19 vaccines prevented over 42 lakh potential deaths in India in 2021, said a study published in The Lancet Infectious Diseases journal, which based its findings on estimates of "excess" mortalities in the country during the pandemic. In the first year of the vaccination programme, 19.8 million out of a potential 31.4 million COVID-19 deaths were prevented worldwide, according to …

Corbevax gets DCGI nod as COVID-19 booster after two doses of Covishield or Covaxin
2 years, 6 months ago

Corbevax gets DCGI nod as COVID-19 booster after two doses of Covishield or Covaxin

The Hindu  

Hyderabad-based Biological E. Limited ’s COVID-19 vaccine Corbevax has been approved by the Drug Controller General of India as a heterologous COVID-19 booster dose to individuals aged 18 years and above after 6 months of administration of primary vaccination of Covaxin or Covishield vaccines for restricted use in emergency situations. ‘’Recently, BE furnished its clinical trials data to the DCGI, …

Corbevax Gets DCGI Approval As Covid-19 Vaccine Booster Dose For 18 Years And Above
2 years, 6 months ago

Corbevax Gets DCGI Approval As Covid-19 Vaccine Booster Dose For 18 Years And Above

ABP News  

New Delhi: The Drug Controller General of India approved the Corbevax Covid-19 booster as heterologous Covid-19 booster dose for adults above the age of 18 years who got their primary Covid-19 vaccination of Covishield or Covaxin administered six months before, reported news agency ANI. Recently, BE has furnished its clinical trials data to the DCGI who after a detailed evaluation …

Corbevax gets DCGI nod as Covid-19 booster dose
2 years, 6 months ago

Corbevax gets DCGI nod as Covid-19 booster dose

India TV News  

Highlights Biological E's Corbevax vaccine has been cleared for a booster dose for those 18 and above. The Drugs Controller General Of India had earlier approved Corbevax, India's first indigenously developed RBD protein subunit vaccine, for restricted use in emergency situations for those aged five and above.A press release from the vaccine maker said the Corbevax can be administered as …

Mix and match of Covid vaccine for booster shots unlikely to be allowed: Report
2 years, 7 months ago

Mix and match of Covid vaccine for booster shots unlikely to be allowed: Report

Live Mint  

The government may not allow the administration of a precaution Covid-19 dose that is different from the one used for primary vaccination, reported news agency PTI, quoting sources, on Thursday. This comes in light of a recent study by the Christian Medical College Vellore, which showed that a booster dose of Covishield after primary vaccination with Covaxin gives 6 to …

Fourth Covid-19 vaccine dose provides strong immunity boost: UK study
2 years, 7 months ago

Fourth Covid-19 vaccine dose provides strong immunity boost: UK study

India TV News  

A fourth dose of the Pfizer or Moderna COVID-19 vaccine is safe and boosts antibody levels, even higher than that of a third dose, according to the latest results from a nationwide study in the UK. The findings, published in The Lancet Infectious Disease journal, show that fourth dose mRNA booster vaccines for COVID-19 are well-tolerated in people who received …

New oral Covid vaccine can decrease severity, transmission: Study
2 years, 7 months ago

New oral Covid vaccine can decrease severity, transmission: Study

India Today  

An investigational Covid vaccine designed to be administered orally has not only limited the degree of the disease but also decreased its airborne spread during its trial on animals, revealed a study published in the journal, Science Translational Medicine, earlier this week. The research team led by Duke University researcher Stephanie N Langel, a medical instructor in the Department of …

New plant-based Covid vaccine 70% effective against variants: Study
2 years, 7 months ago

New plant-based Covid vaccine 70% effective against variants: Study

India Today  

A new plant-based Covid-19 vaccine is nearly 70 per cent effective against symptomatic disease caused by five variants of the coronavirus, according to results of the human clinical trial of the preventive. The study, published on Thursday in the New England Journal of Medicine, shows that the vaccine efficacy was 69.5 per cent against any symptomatic Covid-19 caused by five …

'New plant-based COVID-19 vaccine 70% effective against variants'
2 years, 7 months ago

'New plant-based COVID-19 vaccine 70% effective against variants'

Firstpost  

The vaccine developed by researchers at Canadian biotechnology company Medicago contains coronavirus-like particles produced in plants which are combined with an adjuvant that helps vaccines work better Toronto: A new plant-based COVID-19 vaccine is nearly 70 per cent effective against symptomatic disease caused by five variants of the coronavirus, according to results of the human clinical trial of the preventive. …

AstraZeneca Covid Booster Shot Effective Against Severe Disease, UK Study Finds
2 years, 7 months ago

AstraZeneca Covid Booster Shot Effective Against Severe Disease, UK Study Finds

News 18  

London: The third dose of AstraZeneca COVID-19 vaccine is effective against symptomatic disease and hospitalisation, offering protection comparable to a booster shot of the Pfizer preventive, according to a study conducted in the UK. The results show that after 25 or more weeks since primary vaccination with AstraZeneca, vaccine effectiveness against symptomatic disease post Omicron infection was 8.0 per cent …

India to Participate in Global Trials to Assess Safety of Covishield among Cancer, HIV, Transplant Patients
2 years, 7 months ago

India to Participate in Global Trials to Assess Safety of Covishield among Cancer, HIV, Transplant Patients

News 18  

India will soon kick-start trials to assess the safety and immunity of AstraZeneca’s Covid-19 vaccine, dubbed Covishield in India, among unvaccinated immunocompromised adults, News18.com has learnt. According to the study planned on the global scale, previously unvaccinated immunocompromised adults will be enrolled in five disease cohorts — solid organ transplant, hematopoietic stem cell transplant, solid organ cancer patients receiving cytotoxic …

Covishield Has Least Neutralizing Power against Omicron’s BA.1 Variant, Boosters Needed: NIV Study
2 years, 7 months ago

Covishield Has Least Neutralizing Power against Omicron’s BA.1 Variant, Boosters Needed: NIV Study

News 18  

Covishield recipients with no history of Covid have shown the least neutralizing power against Omicron’s BA.1 variant, a study conducted by the ICMR-National Institute of Virology have found, indicating need for booster shots. Breakthrough cases jabbed with Covishield, however, had highest neutralizing antibodies against all variants studied, than recovered and Covid-naïve vaccinated individuals,” an ICMR scientist told The Times of …

Centre’s decision on mix-and-match boosters likely in two weeks: Official
2 years, 8 months ago

Centre’s decision on mix-and-match boosters likely in two weeks: Official

Hindustan Times  

The government may be able to decide in two weeks whether to mix and match the booster doses of approved Covid-19 vaccines based on India-specific trial data being prepared by the Christian Medical College in Vellore, according to people familiar with the development. CMC Vellore, which was permitted to conduct homologous as well as heterologous booster dose trial by the …

In First Quantitative Sero-survey in Mumbai, 99.93% Participants Found with Covid-19 Antibodies
2 years, 8 months ago

In First Quantitative Sero-survey in Mumbai, 99.93% Participants Found with Covid-19 Antibodies

News 18  

In the first quantitative sero-survey conducted in March this year, COVID-19 antibodies were found in 3,097 out of the 3,099 health and frontline workers, who were examined, the Brihanmumbai Municipal Corporation said. Comparatively, more antibodies were found in the blood samples of the employees, who have taken the preventive or booster doses of COVID-19 vaccines as compared to the fully …

Discover Related